Hospital
ST. Vincent Dunn Hospital INC.
ST. Vincent Dunn Hospital INC. was paid $1.19M by Medicaid between Jan 2018 and Dec 2022, across 73 billing codes. Its largest line is 99283, emergency room visit (moderate) — 43% of everything it billed.
33Billing provider infoST. VINCENT DUNN HOSPITAL INC.
BEDFORD, IN 47421
BEDFORD, IN 47421
33aNPI1497074728assigned 05/26/2010
33bProvider typeCritical Access Hospital
28Total paid$1.19M
24GClaims36,640
24DCodes billed73
24AFirst – last monthJan 2018 – Dec 2022
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#22 of 26
Median peer was paid$4.16M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,283 | $70K | |
| 2019 | 7,406 | $133K | |
| 2020 | 5,497 | $192K | |
| 2021 | 9,608 | $427K | |
| 2022 | 6,846 | $366K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 43% | 3,700 | 3,384 | $508K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 3,093 | 2,592 | $262K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 373 | 292 | $35K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.9% | 759 | 675 | $34K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.5% | 1,093 | 951 | $30K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.5% | 1,093 | 951 | $30K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 637 | 505 | $27K |
| 80053 | Comprehensive metabolic panel | 2.1% | 4,790 | 4,013 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 551 | 485 | $24K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.0% | 1,205 | 1,040 | $23K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 212 | 164 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 5,011 | 4,171 | $19K |
61 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 353 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 987 | $11K |
| 80306 | <1% | 1,077 | $11K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 374 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 253 | $9K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 188 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 76 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 96 | $6K |
| 82607 | <1% | 557 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 799 | $5K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 24 | $5K |
| 83880 | <1% | 277 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 374 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 647 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 43 | $3K |
| 87481 | <1% | 193 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 192 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 51 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 145 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,237 | $3K |
| 82746 | <1% | 280 | $3K | |
| 83605 | <1% | 465 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $3K |
| 87088 | <1% | 425 | $2K | |
| 84484 | <1% | 362 | $2K | |
| 86803 | <1% | 171 | $2K | |
| 80061 | Lipid panel | <1% | 184 | $2K |
| 81001 | <1% | 1,297 | $2K | |
| 87634 | <1% | 16 | $842.40 | |
| 83690 | <1% | 279 | $723.44 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 79 | $716.38 |
| 80081 | <1% | 12 | $688.69 | |
| 82728 | <1% | 96 | $669.62 | |
| 80055 | <1% | 14 | $543.26 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 44 | $515.72 |
| 84439 | <1% | 62 | $455.00 | |
| 83735 | <1% | 117 | $419.15 | |
| 85730 | <1% | 91 | $314.17 | |
| 85027 | <1% | 286 | $251.37 | |
| 87430 | <1% | 28 | $237.94 | |
| 85610 | <1% | 116 | $231.13 | |
| 87510 | <1% | 17 | $216.10 | |
| 87660 | <1% | 17 | $216.10 | |
| 87480 | <1% | 17 | $212.10 | |
| 82950 | <1% | 42 | $189.42 | |
| 87807 | <1% | 20 | $179.67 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 154 | $154.02 |
| 83655 | <1% | 13 | $141.00 | |
| 81025 | <1% | 29 | $92.63 | |
| 87081 | <1% | 13 | $88.18 | |
| 87040 | <1% | 22 | $82.82 | |
| 86592 | <1% | 13 | $56.79 | |
| 86850 | <1% | 14 | $25.25 | |
| 85018 | <1% | 26 | $20.08 | |
| 85014 | <1% | 26 | $20.08 | |
| J2704 | Injection, propofol, 10 mg | 0% | 18 | $0.00 |
| A9270 | Non-covered item or service | 0% | 26 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 17 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 233 | $0.00 |
| 90791 | Psychiatric diagnostic evaluation | 0% | 14 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZHANG, GEORGE (CEO, ADMINISTRATOR)